• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form DEFA14A filed by Edwards Lifesciences Corporation

    3/26/25 4:17:28 PM ET
    $EW
    Industrial Specialties
    Health Care
    Get the next $EW alert in real time by email
    DEFA14A 1 ewnaa.htm DEFA14A ewnaa
    UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Definitive Proxy Statement ☒ Definitive Additional Materials ☐ Soliciting Material under §240.14a-12 Edwards Lifesciences Corporation (Name of Registrant as Specified In Its Charter) (Name of Person(s) Filing Proxy Statement, if other than the Registrant) Payment of Filing Fee (Check the appropriate box): ☒ No fee required. ☐ Fee paid previously with preliminary materials. ☐ Fee computed on table in exhibit required by Item 25(b) per Exchange Act Rules 14a-6(i)(1) and 0- 11.


     
    Your control number Your vote matters! Meeting Materials: Notice of Meeting and Proxy Statement & Annual Report or Form 10-K Important Notice Regarding the Availability of Proxy Materials for the Annual Meeting of Stockholders To Be Held On May 8, 2025 For Stockholders of Record as of March 11, 2025 To request paper materials, use one of the following methods. Internet: www.investorelections.com/EW Call: 1-866-648-8133 Email: [email protected] * If requesting material by e-mail, please send a blank e-mail with the 12 digit control number (located below) in the subject line. No other requests, instructions OR other inquiries should be included with your e-mail requesting paper materials. Have the 12 digit control number located in the box above available when you access the website and follow the instructions. Copyright © 2025 BetaNXT, Inc. or its affiliates. All Rights Reserved Edwards Lifesciences Corporation Annual Meeting of Stockholders Thursday, May 8, 2025 10:00 AM, Pacific Time Annual Meeting to be held via the Internet Please visit www.proxydocs.com/EW for more details and to view the proxy materials You must register to attend the meeting online at www.proxydocs.com/EW For a convenient way to view proxy materials, VOTE, and obtain directions to attend the meeting, visit www.proxydocs.com/EW. To vote your proxy while visiting this site, you will need the 12 digit control number in the box below. This communication presents only an overview of the more complete proxy materials that are available to you on the Internet. This is not a ballot. You cannot use this notice to vote your shares by mail. We encourage you to access and review all of the important information contained in the proxy materials before voting. Under United States Securities and Exchange Commission rules, proxy materials do not have to be delivered in paper. Proxy materials can be distributed by making them available on the internet. If you want to receive a paper or e-mail copy of the proxy materials, you must request one. There is no charge to you for requesting a copy. In order to receive a paper package in time for this year's meeting, you must make this request on or before April 28, 2025. styleINA P.O. BOX 8016, CARY, NC 27512-9903 SEE REVERSE FOR FULL AGENDA Go Green! To receive documents via e-mail, simply go to: www.proxypush.com/EW


     
    PROPOSAL 1. Election of Directors 1.01 Leslie C. Davis 1.02 David T. Feinberg, MD 1.03 Kieran T. Gallahue 1.04 Leslie S. Heisz 1.05 Paul A. LaViolette 1.06 Steven R. Loranger 1.07 Ramona Sequeira 1.08 Nicholas J. Valeriani 1.09 Bernard J. Zovighian 2. Advisory Vote to Approve Named Executive Officer Compensation 3. Ratification of Appointment of Independent Registered Public Accounting Firm 4. Approval of the Amendment and Restatement of the Company's 2001 Employee Stock Purchase Plan for United States Employees (the "U.S. ESPP") to Increase the Total Number of Shares of Common Stock Available for Issuance under the U.S. ESPP by 4,200,000 Shares 5. Approval of the Amendment and Restatement of the Company's 2001 Employee Stock Purchase Plan for International Employees (the"International ESPP") to Increase the Total Number of Shares of Common Stock Available for Issuance under the International ESPP by 1,460,000 Shares THE BOARD OF DIRECTORS RECOMMENDS A VOTE: FOR ALL PROPOSALS BEING PRESENTED Edwards Lifesciences Corporation Annual Meeting of Stockholders


     
    Get the next $EW alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $EW

    DatePrice TargetRatingAnalyst
    1/9/2026$97.00Hold → Buy
    TD Cowen
    12/18/2025$100.00Neutral → Overweight
    Analyst
    11/3/2025$96.00Mkt Perform → Outperform
    Raymond James
    10/29/2025Underperform → Peer Perform
    Wolfe Research
    10/29/2025$98.00Hold → Buy
    Jefferies
    10/8/2025Outperform → Perform
    Oppenheimer
    10/7/2025$88.00In-line → Outperform
    Evercore ISI
    7/29/2025$100.00Neutral → Buy
    BTIG Research
    More analyst ratings

    $EW
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    CVP, TAVR Lippis Daniel J. was granted 12,820 shares and covered exercise/tax liability with 456 shares, increasing direct ownership by 56% to 34,366 units (SEC Form 4)

    4 - Edwards Lifesciences Corp (0001099800) (Issuer)

    2/17/26 5:16:02 PM ET
    $EW
    Industrial Specialties
    Health Care

    CVP, Chief Financial Officer Ullem Scott B. covered exercise/tax liability with 199 shares, decreasing direct ownership by 0.50% to 39,699 units (SEC Form 4)

    4 - Edwards Lifesciences Corp (0001099800) (Issuer)

    2/17/26 5:16:03 PM ET
    $EW
    Industrial Specialties
    Health Care

    CEO Zovighian Bernard J sold $1,719,741 worth of shares (22,430 units at $76.67), gifted 2,920 shares, received a gift of 2,920 shares and exercised 25,350 shares at a strike of $59.26 (SEC Form 4)

    4 - Edwards Lifesciences Corp (0001099800) (Issuer)

    2/13/26 5:37:29 PM ET
    $EW
    Industrial Specialties
    Health Care

    $EW
    SEC Filings

    View All

    Edwards Lifesciences Corporation filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    8-K - Edwards Lifesciences Corp (0001099800) (Filer)

    2/10/26 4:22:48 PM ET
    $EW
    Industrial Specialties
    Health Care

    Edwards Lifesciences Corporation filed SEC Form 8-K: Regulation FD Disclosure

    8-K - Edwards Lifesciences Corp (0001099800) (Filer)

    1/9/26 6:51:56 PM ET
    $EW
    Industrial Specialties
    Health Care

    SEC Form 10-Q filed by Edwards Lifesciences Corporation

    10-Q - Edwards Lifesciences Corp (0001099800) (Filer)

    11/5/25 4:12:51 PM ET
    $EW
    Industrial Specialties
    Health Care

    $EW
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Zovighian Bernard J covered exercise/tax liability with 4,245 shares, converted options into 6,265 shares and bought $49,753 worth of shares (580 units at $85.74), increasing direct ownership by 5% to 46,836 units (SEC Form 4)

    4 - Edwards Lifesciences Corp (0001099800) (Issuer)

    5/7/24 5:53:27 PM ET
    $EW
    Industrial Specialties
    Health Care

    $EW
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    $EW
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Edwards Lifesciences to Present at the Barclays and Leerink Partners Global Healthcare Conferences

    Edwards Lifesciences Corporation (NYSE:EW) today announced its chief financial officer, Scott Ullem, is scheduled to present at two upcoming conferences: Tuesday, March 10, 2026 at 10:00 a.m. ET at the Barclays 28th Annual Global Healthcare Conference Wednesday, March 11, 2026 at 10:00 a.m. ET at the Leerink Global Healthcare Conference A live webcast of each presentation will be available on the Edwards investor relations website at http://ir.edwards.com/, with an archived version accessible later the same day. About Edwards Lifesciences Edwards Lifesciences is the leading global structural heart innovation company, driven by a passion to improve patient lives. Through breakth

    2/19/26 7:05:00 AM ET
    $EW
    Industrial Specialties
    Health Care

    Edwards Lifesciences to Present at Citi's 2026 Unplugged Medtech and Life Sciences Access Day

    Edwards Lifesciences Corporation (NYSE:EW) today announced it will participate in Citi's Unplugged Medtech and Life Sciences Access Day on February 26, 2026. Scott Ullem, chief financial officer, is scheduled to present at 10:15 a.m. ET. A live webcast of the presentation will be available on the Edwards Lifesciences investor relations website at http://ir.edwards.com/, with an archived version accessible later the same day. About Edwards Lifesciences Edwards Lifesciences is the leading global structural heart innovation company, driven by a passion to improve patient lives. Through breakthrough technologies, world-class evidence and partnerships with clinicians and healthcare stakeho

    2/13/26 7:05:00 AM ET
    $EW
    Industrial Specialties
    Health Care

    Edwards Lifesciences Reports Fourth Quarter Results

    Edwards Lifesciences (NYSE:EW) today reported financial results for the quarter and full-year ended Dec. 31, 2025. Highlights and Outlook Q4 sales grew 13.3% to $1.57 billion1, constant currency2 sales grew 11.6% Q4 TAVR sales grew 12.0% to $1.16 billion1; constant currency2 sales grew 10.6% Q4 TMTT sales grew more than 40% to $156 million1 from repair and replacement therapies Q4 EPS of $0.111; adjusted2 EPS of $0.58 FY 2025 sales grew 11.5%, 10.7% constant currency2 Increased confidence in FY 2026 constant currency2 sales growth of 8 – 10% FY 2026 revenue outlook includes TMTT growing 35 – 45% to $740 – $780 million Increased confidence in FY 2026 adjusted2 EPS $

    2/10/26 4:15:00 PM ET
    $EW
    Industrial Specialties
    Health Care

    Edwards Lifesciences upgraded by TD Cowen with a new price target

    TD Cowen upgraded Edwards Lifesciences from Hold to Buy and set a new price target of $97.00

    1/9/26 8:27:58 AM ET
    $EW
    Industrial Specialties
    Health Care

    Edwards Lifesciences upgraded by Analyst with a new price target

    Analyst upgraded Edwards Lifesciences from Neutral to Overweight and set a new price target of $100.00

    12/18/25 8:41:18 AM ET
    $EW
    Industrial Specialties
    Health Care

    Edwards Lifesciences upgraded by Raymond James with a new price target

    Raymond James upgraded Edwards Lifesciences from Mkt Perform to Outperform and set a new price target of $96.00

    11/3/25 9:08:28 AM ET
    $EW
    Industrial Specialties
    Health Care

    $EW
    Financials

    Live finance-specific insights

    View All

    Edwards Lifesciences Reports Fourth Quarter Results

    Edwards Lifesciences (NYSE:EW) today reported financial results for the quarter and full-year ended Dec. 31, 2025. Highlights and Outlook Q4 sales grew 13.3% to $1.57 billion1, constant currency2 sales grew 11.6% Q4 TAVR sales grew 12.0% to $1.16 billion1; constant currency2 sales grew 10.6% Q4 TMTT sales grew more than 40% to $156 million1 from repair and replacement therapies Q4 EPS of $0.111; adjusted2 EPS of $0.58 FY 2025 sales grew 11.5%, 10.7% constant currency2 Increased confidence in FY 2026 constant currency2 sales growth of 8 – 10% FY 2026 revenue outlook includes TMTT growing 35 – 45% to $740 – $780 million Increased confidence in FY 2026 adjusted2 EPS $

    2/10/26 4:15:00 PM ET
    $EW
    Industrial Specialties
    Health Care

    Edwards Lifesciences to Host Earnings Conference Call on February 10, 2026

    Edwards Lifesciences (NYSE:EW) plans to announce its operating results for the quarter ended December 31, 2025 after the market closes on Tuesday, February 10, and will host a conference call at 5:00 p.m. ET that day to discuss those results. To participate in the conference call, dial (877) 704-2848 or (201) 389-0893. The call will also be available live and archived on the "Investor Relations" section of the Edwards website at ir.edwards.com. About Edwards Lifesciences Edwards Lifesciences is the leading global structural heart innovation company, driven by a passion to improve patient lives. Through breakthrough technologies, world-class evidence and partnerships with clinicians an

    2/3/26 7:05:00 AM ET
    $EW
    Industrial Specialties
    Health Care

    Edwards Lifesciences Reaffirms Strategy for Sustainable, Differentiated Growth at Annual Investor Conference

    Innovation with Purpose, Powered by Science, Centered on Patients: Edwards' Commitment to Drive Value for the Healthcare Ecosystem Edwards Lifesciences (NYSE:EW) will outline its patient-focused strategy and share financial guidance during its annual investor conference. Entering 2026 with momentum for sustainable differentiated growth, Edwards is uniquely positioned with leading therapies across its core structural heart innovations for patients with aortic stenosis (AS), mitral regurgitation (MR), tricuspid regurgitation (TR) and pulmonic diseases, and expanding into emerging opportunities to advance treatments for aortic regurgitation (AR) and structural heart failure. "As we enter 202

    12/4/25 9:00:00 AM ET
    $EW
    Industrial Specialties
    Health Care

    $EW
    Leadership Updates

    Live Leadership Updates

    View All

    Edwards Lifesciences Announces CFO Transition Plan

    Edwards Lifesciences (NYSE:EW) today announced that Scott Ullem, the company's chief financial officer, has decided to transition from his role by midyear 2026. While the company initiates a selection process to appoint a new CFO, this planned transition will enable continuity and a smooth transfer of responsibilities. Following the appointment of a new CFO, Ullem will continue in an advisory role. About Edwards Lifesciences Edwards Lifesciences is the leading global structural heart innovation company, driven by a passion to improve patient lives. Through breakthrough technologies, world-class evidence and partnerships with clinicians and healthcare stakeholders, our employees are insp

    10/30/25 4:15:00 PM ET
    $EW
    Industrial Specialties
    Health Care

    Pulnovo Medical Names Dr. Francis Duhay as Global Chief Medical Officer

    SHANGHAI, Aug. 25, 2025 /PRNewswire/ -- Pulnovo Medical, a global leader in mechanism-driven therapies for Pulmonary Hypertension (PH) and Heart Failure (HF), today announced the appointment of Francis Duhay, MD, MBA, FACS as Global Chief Medical Officer. Dr. Duhay, a board-certified General and Cardiothoracic Surgeon, brings over 25 years of experience in clinical medicine, medical device innovation, and executive leadership. As former Chief Medical Officer at Edwards Lifesciences (NYSE:EW), he played a decisive role in the development, clinical validation, and worldwide adoption of Transcatheter Aortic Valve Replacement (TAVR)—a transformative therapy now recognized as one of the most suc

    8/25/25 4:33:00 AM ET
    $EW
    Industrial Specialties
    Health Care

    Scaling its Investment Platform in Minimally Invasive Care, Intuitive Ventures Appoints Terri Burke as Senior Partner and Ross Jaffe as Venture Advisor

    Intuitive Ventures today announced the appointment of Terri Burke, former head medtech investments at Epidarex Capital and a seasoned operator, as Senior Partner and Dr. Ross Jaffe, a co-founder of Versant Ventures, as Venture Advisor. Both medtech veterans, they will help support the continued growth of Intuitive Ventures in investing in start-ups reimagining the future of minimally invasive care. With more than two decades of medtech investing and operational leadership experience, Burke will help support the growth of the firm's investment platform. With over $250 million in assets under management, Intuitive Ventures invests in founders tackling large, meaningful problems that positive

    3/6/25 8:00:00 AM ET
    $EW
    Industrial Specialties
    Health Care

    $EW
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by Edwards Lifesciences Corporation

    SC 13G - Edwards Lifesciences Corp (0001099800) (Subject)

    11/8/24 10:34:33 AM ET
    $EW
    Industrial Specialties
    Health Care

    Amendment: SEC Form SC 13G/A filed by Edwards Lifesciences Corporation

    SC 13G/A - Edwards Lifesciences Corp (0001099800) (Subject)

    10/4/24 2:14:28 PM ET
    $EW
    Industrial Specialties
    Health Care

    SEC Form SC 13G/A filed by Edwards Lifesciences Corporation (Amendment)

    SC 13G/A - Edwards Lifesciences Corp (0001099800) (Subject)

    2/13/24 5:04:42 PM ET
    $EW
    Industrial Specialties
    Health Care